Patent intelligence · US
US 11033539
Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological…
Patent details — US 11033539
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 15, 2021
- Expiration
- Jun 10, 2041
- Applicant
- Neurocrine Biosciences, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/496
Quick answer
US 11033539 (Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Neurocrine Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/496, A61K31/506, A61K31/519
More from Neurocrine Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421193
GPR52 modulators and methods of use
granted -
US 12383536
CRF receptor antagonists and methods of use
granted -
US 12128033
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
granted -
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 12083227
Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 11730739
Treatment of congenital adrenal hyperplasia
granted -
US 11718618
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
granted -
US 11713324
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
granted
Frequently asked questions
What is US patent 11033539?
US 11033539 (Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases) is held by Neurocrine Biosciences, Inc.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11033539?
Neurocrine Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 111 pharmaceutical patents for this assignee.
When does US 11033539 expire?
Our index shows an expiration date of Jun 10, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.